Antibe Therapeutics Inc(Pre-Merger) ATBPF

Upcoming ...

[MrMugsy]

Yes - as per webinar ... IBD update before Christmas.

Then IND work begins in the New Year for IBD and for one other - but - the one other may first depend on a 346 vs. 352 head-to-head investigation.

Then we're waiting for human pills to arrive (March-ish) - complete PK study - go into P2.

-----------------

A few other things but that's the bigger part of it.

[woundedknee]

A bit off topic, but i just finished watching an episode from Tucker Carlson Today, interviewing Dr. Aeem Malhotra from the UK. The main theme of his talk is why the covid vacinnes are dangerous and should not be taken. But there was one bit of info he revealed that I did not know and that is that the FDA receives 60% of its funding from Big Pharma. Seems like a conflict of interest to me and also

[Inthepez]

Or have a (previous) FDA insider who knows the right people. One would assume Stauffer will play a bigger role down the line. 

[Wriggles]

Your point is well taken about big pharma and their state politicians attempting to influence FDA decisions, in general.  In this case, I recall that the AME study was conducted under the auspices of Health Canada and that the FDA was not involved.  From ATE's August 2021 news release:   "The Company will continue to collect and analyze additional data over the next

[MrMugsy]

Biggest conflict I've paid attention to w.r.t FDA is the Biogen AD drug and how professionals started quitting FDA one by one after Aduhelm was approved - even after all 10 said "do not pass" Biogen and FDA certainly looked bad (FDA in Biogen's back pocket) but it didn't go unnoticed.  It started a huge review and a major problem for both FDA and Biogen. Anyway - even

[nobeard]

Has there been any mention of Nunance and how they might fit into this?

[MrMugsy]

Yes - a couple points on Nuance First, Nuance will likely own all rights to OTENA ... be it acute and/or chronic Second, there are some wording issues in the agreement for ATE/Nuance to figure out ATE wants Nuance as a partner so they will figure it out. ---------------- Comments from Dan on this - one of the last two webinars (can't remember which one).

[woundedknee]

About time for Dan to sell some more of his shares. Christmas bills coming up. lol

[MrMugsy]

Hahaha - I don't think it works that way but I could be wrong. I think he covered some future capital gains on the sale of Antibe Holdings - but - maybe I'm wrong.  I would have done that myself. Also - I'd be more concerned about unexpected sales like the one by Wallace out of nowhere.  The unknown and unexpected is a little harder to swallow.  Then again, to sell at

[Benedictus]

  Mugs, I always appreciate your insights and optimism but a share buyback threat would have been an awful bluff and a tell of inept management.  They need every damn penny on hand and then some...and the market knows it.  I'm pleased they're just sticking to their knitting, don't need to dilute near term and moving everything forward. 2023 should be a better year for

[MrMugsy]

I agree Benedictus ... I'm just kidding. By the end of 2022, we'll have $42.5 MM in the bank and we need a minimum of 2 years runway. We also need cash on hand to pay for specialists as situations call for it. I think we spent $2 MM on Liver Specialists. We probably spent some money figuring out the amorphous solution. I wouldn't doubt we spent money developing a superoxide scavenger

[Benedictus]

  Yes and hopefully the quarterly burn rate is a little lower with acute than chronic. I appreciated Dan stressing their intention toward financial prudence. Capital is obviously extremely hard to come by nowadays. A 352 head to head comparison would be very interesting.

[MrMugsy]

Yes ... the 346 and 352 head-2-head is interesting but like everything else ... it's still comes with a whole lot of confusion. For example, I know 352 has always been Ketoprofen based. But, I also know they're sniffing around Ketorolac for a little while. Is this one path or is this two paths for 352 ?  Don't know. Going into 2023, there will be two IND studies as per Dan. One

[StockingUp21]

Bad luck opinion or setting up for soft landing